Kenvue Inc. is a consumer health company globally.
| Revenue (TTM) | $15.41B |
| Gross Profit (TTM) | $9.00B |
| EBITDA | $3.48B |
| Operating Margin | 19.40% |
| Return on Equity | 15.60% |
| Return on Assets | 6.99% |
| Revenue/Share (TTM) | $8.04 |
| Book Value | $5.50 |
| Price-to-Book | 3.45 |
| Price-to-Sales (TTM) | 2.34 |
| EV/Revenue | 2.849 |
| EV/EBITDA | 13.66 |
| Quarterly Earnings Growth (YoY) | 8.50% |
| Quarterly Revenue Growth (YoY) | 3.00% |
| Shares Outstanding | $1.92B |
| Float | $1.92B |
| % Insiders | 0.07% |
| % Institutions | 96.01% |
Volatility is currently contracting
Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.
KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.
Australia's competition regulator on Wednesday approved Kimberly-Clark's proposed $40 billion takeover of Kenvue , on condition the company divests Kenvue's Carefree and Stayfree period care brands in the country to address competition concerns.
Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.
Accomplished legal executive and global litigator brings proven track record of enterprise risk management and strategic leadership to support Kimberly-Clark's next chapter of growth DALLAS, Aug. 13, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) today announced the appointment of Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026. She will report to Jeff Melucci, Chief Strategy, Business Development and Administrative Officer, and will become a member of Kimberly-Clark's Executive Leadership Team.
KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.
Shares of Kenvue (NYSE:KVUE | KVUE Price Prediction) closed at $19.18 on August 6, slipping 2.5% after the consumer health giant posted a rare earnings miss.
Kenvue posts higher Q2 sales and earnings, but both miss estimates as inflation, tariffs and foreign exchange pressure margins.
Kenvue Inc (NYSE:KVUE) shares fell about 2% on Thursday after the consumer health company reported second quarter results that narrowly missed Wall Street expectations, while margins declined from a year earlier. The company reported adjusted diluted earnings per share of $0.31, compared with the $0.32 consensus estimate.
Kenvue (KVUE) came out with quarterly earnings of $0.31 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.29 per share a year ago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on KVUE and any ticker you trade — then tracks every position and per-strategy win rate.
